A concurrent resolution expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.

Calls for the Food and Drug Administration (FDA) to reverse its policy that aims to eliminate patient access to compounded medications containing estriol prescribed by physicians unless it holds a public comment period on the issue and can document evidence of adverse events and other safety issues to justify such policy.